Cabozantinib for the treatment of solid tumors: a systematic review.
Pablo M ReyCamillo PortaJaume CapdevilaAndrea B ApoloSantiago ViteriCristina Rodriguez-AntonaLidia MartinDaniel CastellanoPublished in: Therapeutic advances in medical oncology (2022)
The identified evidence demonstrates the positive efficacy/effectiveness of cabozantinib monotherapy in various solid tumor types, with safety findings being consistent with those observed with other VEGFR-targeting tyrosine kinase inhibitors. When available, real-world findings were consistent with the data reported from clinical trials. A limitation of this review is the high proportion of abstracts; however, this allowed us to capture the most up-to-date findings.